Literature DB >> 10653284

Clinical features of Alzheimer's disease.

H Förstl1, A Kurz.   

Abstract

The preclinical stage of Alzheimer's disease is inconspicuous and there are - almost by definition - no reliable and valid symptoms and signs which would allow a very early diagnosis before the manifestation of irreversible deficits. For a clinical diagnosis of dementia, cognitive impairment has to be severe enough to compromise the activities of daily living. In the mild dementia stage, difficulties with declarative memory are usually prominent; depressive symptoms are not infrequent, but the patient usually manages to live alone. Supervision is needed in the moderate dementia stage, when other cognitive domains are affected in a more obvious manner and non-cognitive disturbances of thought, perception, affect, and behavior put increasing stress on the caregivers. Complete dependence of the patients, who frequently develop neurological disturbances, is typical of the late stage of illness. The life expectancy of patients with a clinical diagnosis of Alzheimer's disease is significantly reduced, but to date there is hope that the period of relative well-being and not of suffering can be prolonged with modern symptomatic treatment interventions.

Entities:  

Mesh:

Year:  1999        PMID: 10653284     DOI: 10.1007/s004060050101

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  79 in total

1.  Normative data for a battery of free recall, cued recall and recognition tests in the elderly Italian population.

Authors:  Emanuele Coluccia; Nadia Gamboz; Maria A Brandimonte
Journal:  Neurol Sci       Date:  2011-09-15       Impact factor: 3.307

2.  Is the Alzheimer's disease cortical thickness signature a biological marker for memory?

Authors:  Edgar Busovaca; Molly E Zimmerman; Irene B Meier; Erica Y Griffith; Stuart M Grieve; Mayuresh S Korgaonkar; Leanne M Williams; Adam M Brickman
Journal:  Brain Imaging Behav       Date:  2016-06       Impact factor: 3.978

Review 3.  Network functional connectivity and whole-brain functional connectomics to investigate cognitive decline in neurodegenerative conditions.

Authors:  O Dipasquale; Mara Cercignani
Journal:  Funct Neurol       Date:  2016 Oct/Dec

Review 4.  The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease.

Authors:  John Grizzanti; Hyoung-Gon Lee; Antoni Camins; Merce Pallas; Gemma Casadesus
Journal:  Nutr Res       Date:  2016-11-08       Impact factor: 3.315

5.  Curcumin Targeted, Polymalic Acid-Based MRI Contrast Agent for the Detection of Aβ Plaques in Alzheimer's Disease.

Authors:  Rameshwar Patil; Pallavi R Gangalum; Shawn Wagner; Jose Portilla-Arias; Hui Ding; Arthur Rekechenetskiy; Bindu Konda; Satoshi Inoue; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Macromol Biosci       Date:  2015-06-02       Impact factor: 4.979

6.  Predicting regional neurodegeneration from the healthy brain functional connectome.

Authors:  Juan Zhou; Efstathios D Gennatas; Joel H Kramer; Bruce L Miller; William W Seeley
Journal:  Neuron       Date:  2012-03-21       Impact factor: 17.173

7.  Delayed audiovisual integration of patients with mild cognitive impairment and Alzheimer's disease compared with normal aged controls.

Authors:  Jinglong Wu; Jiajia Yang; Yinghua Yu; Qi Li; Naoya Nakamura; Yong Shen; Yasuyuki Ohta; Shengyuan Yu; Koji Abe
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

8.  Neuropsychiatric symptoms in severe dementia: Associations with specific cognitive domains the Cache County Dementia Progression Study.

Authors:  William J Rozum; Bryce Cooley; Elizabeth Vernon; Joshua Matyi; JoAnn T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2019-04-25       Impact factor: 3.485

Review 9.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22

10.  Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen Aronson; Bart Van Baelen; Shane Kavanagh; Susanne Schwalen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.